IRLA · XBRL financial data

Quince Therapeutics financial statements, every fiscal year

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (IRLA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	61,307	60,795	25,178	9,447	18,590	35,382
General and administrative	17,586	29,523	26,012	17,695	17,580	15,047
Total operating expenses	78,893	90,318	52,015	34,620	57,285	58,068
Operating income (loss)	(78,893)	(90,318)	(52,015)	(34,620)	(57,285)	(58,068)
Interest income	2,044	620	1,068	3,478	2,929	1,244
Other income (expense)	0	(247)	(997)	(102)	(676)	486
Income tax expense (benefit)	0	0	(284)	197	87	3,214
Net income (loss)	(76,849)	(89,945)	(51,660)	(31,385)	(56,828)	(83,979)
Earnings per share, basic USD per share	—	(3.03)	(1.54)	(0.84)	(1.31)	(1.68)
Earnings per share, diluted USD per share	—	(3.03)	(1.54)	(0.84)	(1.31)	(1.68)
Weighted average shares, basic thousands of shares	—	29,719	33,497	37,237	43,262	50,097
Weighted average shares, diluted thousands of shares	—	29,719	33,497	37,237	43,262	50,097

Fiscal years (IRLA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	66,841	29,454	40,593	20,752	6,212	5,809
Short-term investments	—	—	—	—	—	11,943
Marketable securities	66,979	37,078	45,602	54,307	34,572	11,943
Marketable securities, non-current	50,464	19,933	3,578	0	—	—
Prepaid and other current assets	4,042	4,871	3,567	2,381	3,252	5,144
Total current assets	137,862	111,673	93,748	77,440	44,036	22,896
Property and equipment, net	427	263	393	234	315	595
Right-of-use asset	674	1,165	291	385	498	453
Goodwill	—	0	0	17,625	0	—
Total assets	189,466	133,228	103,910	167,900	114,478	93,523
Accounts payable	3,555	4,911	570	2,033	2,903	2,223
Accrued liabilities	13,441	9,311	2,499	3,436	4,375	10,608
Current portion of long-term debt	—	—	—	—	0	18,026
Total current liabilities	16,996	14,222	3,069	9,572	7,278	43,226
Lease liability, non-current	208	420	0	321	394	330
Total liabilities	17,204	14,642	3,317	82,816	84,332	129,237
Accumulated deficit	(146,654)	(236,599)	(288,259)	(319,644)	(376,472)	(460,451)
Total stockholders' equity	172,262	118,586	100,593	85,084	30,146	(35,714)
Total liabilities and equity	189,466	133,228	103,910	167,900	114,478	93,523
Common shares outstanding (cover page) thousands of shares	29,552	30,146	36,277	43,215	44,002	163,008

Fiscal years (IRLA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(76,849)	(89,945)	(51,660)	(31,385)	(56,828)	(83,979)
Stock-based compensation	14,470	29,853	16,618	5,220	4,746	5,105
Net cash from operating activities	(50,818)	(62,932)	(44,038)	(18,292)	(31,904)	(41,425)
Purchases of property and equipment	52	180	133	160	257	352
Net cash from investing activities	(52,431)	58,952	18,002	(5,758)	21,908	23,227
Proceeds from issuing common stock	—	0	608	0	—	—
Net cash from financing activities	118,876	6,808	707	143	(4,775)	17,909
Net change in cash	15,627	2,883	(25,145)	(23,827)	(14,540)	(403)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Quince Therapeutics	115,981	not reported	(18,887)*	1.0M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.